PT - JOURNAL ARTICLE AU - Bari, Bilal A. AU - Krystal, Andrew D. AU - Pizzagalli, Diego A. AU - Gershman, Samuel J. TI - Computationally-informed insights into anhedonia and treatment by <em>κ</em>-opioid receptor antagonism AID - 10.1101/2024.04.09.24304873 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.09.24304873 4099 - http://medrxiv.org/content/early/2024/04/10/2024.04.09.24304873.short 4100 - http://medrxiv.org/content/early/2024/04/10/2024.04.09.24304873.full AB - Anhedonia, the loss of pleasure, is prevalent and impairing. Parsing its computational basis promises to explain its transdiagnostic character. We argue that one manifestation of anhedonia— reward insensitivity—may be linked to limited memory capacity. Further, the need to economize on limited capacity engenders a perseverative bias towards frequently chosen actions. Anhedonia may also be linked with deviations from optimal perseveration for a given memory capacity, a pattern that causes inefficiency because it results in less reward for the same memory cost. To test these hypotheses, we perform secondary analysis of a randomized controlled trial testing κ-opioid receptor (KOR) antagonism for anhedonia, as well as analyses of three other datasets. We find that anhedonia is associated with deficits in efficiency but not memory, whereas KOR antagonism (which likely elevates tonic dopamine) increases memory and efficiency. KOR antagonism therefore has distinct cognitive effects, only one related to anhedonia.Competing Interest StatementA.D.K. has been a consultant for Eisai, Axsome, Big Health, Harmony, Idorsia, Jazz, Janssen, Takeda, Millenium Merck, Neurocrine, Neurawell, Otsuka, Evecxia and Sage Research and received support from the NIH, the Ray and Dagmar Dolby Family Fund, Janssen, Jazz. Neurocrine, Attune, Harmony, and Axsome. Over the past 3 years, D.A.P. has received consulting fees from Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Karla Therapeutics, Neumora Therapeutics, Neurocrine Biosciences, Neuroscience Software, Otsuka, Sage Therapeutics, Sama Therapeutics, Sunovion Therapeutics, and Takeda; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) as well as Alkermes; he has received research funding from the Brain and Behavior Research Foundation, Dana Foundation, Wellcome Leap, Millennium Pharmaceuticals, and NIMH; he has received stock options from Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software. D.A.P. has a financial interest in Neumora Therapeutics, which has licensed the copyright to the PRT through Harvard University. The interests of D.A.P. were reviewed and are managed by McLean Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. B.A.B. and S.J.G. declare no competing interests.Clinical TrialNCT02218736Funding StatementThis work was supported by National Institute of Mental Health grants R25MH094612 (B.A.B.), R37MH068376 and R01MH101521 (D.A.P.), HHS-N271-2012-000006-I (A.D.K.), and the Harvard Brain Science Initiative Bipolar Disorder Seed Grant (S.J.G.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Harvard University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe KOR dataset is available in the National Institute of Mental Health (NIMH) Data Archive repository and can be accessed by contacting the NIMH Data Archive at the following email address: NDAHelp{at}mail.nih.gov. Other data included in the present study are available upon reasonable request to the authors.